Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Immunol.

Sec. Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders

This article is part of the Research TopicOrgan-Specific Autoimmune and Rare Diseases: Quantitative Modeling Approaches in Support of the Biology, Disease Progression, Pharmacology, and Developments of TherapiesView all articles

Changes in Circulating NK and Innate-Like T Cells in Type 1 and Type 2 Diabetes

Provisionally accepted
  • 1Endocrinology Research Centre, Moscow, Russia
  • 2Institut vycislitel'noj matematiki imeni G I Marcuka Rossijskoj akademii nauk, Moscow, Russia

The final, formatted version of the article will be published soon.

Background: Inflammatory responses that accompany the progression of type 1 (T1D) and type 2 diabetes mellitus (T2D) are fundamentally distinct in their underlying nature. T1D is predominantly driven by autoimmune-mediated inflammation, whereas T2D is characterised by a chronic, low-grade metabolic inflammation. A growing body of evidence has highlighted the involvement of natural killer (NK) cells in pathophysiology of both forms of diabetes; nevertheless, the precise mechanisms and the roles played by specific NK cell subsets remain incompletely understood. Methods: Multicolour flow cytometry was used to identify several NK and innate-like T cell subpopulations in peripheral blood of patients with adult-onset T1D (n=23) and T2D (n=14) in comparison to healthy volunteers (n=24). Subset identification was based on expression of functional antigens (CD16 and CD56), co-receptors (CD8 and CD38), inhibitory receptors (NKG2A and CD161), and transcription factor EOMES. Quantitative analysis using Spearman's rank correlation coefficients was performed to identify possible association between immune and clinical parameters and to rank the clinical parameters with respect to the number of connections with immune cell populations. Results: T1D was accompanied by a reduction in overall NK cells and their dominant cytolytic CD56dimCD16bright subpopulation. Also a 50% increase in frequency of CD8+ NK cells was observed together with a growth of CD8+CD38+, CD8+CD161+, CD8+NKG2A+, and CD8+EOMES+ NK subsets. T2D was associated with a more than twofold decrease in the frequency of MAIT cell subset within CD8+ T cell population. Correlation analysis of the obtained data set revealed quantitative relationships between immune status parameters and clinical indicators, highlighting the involvement of NK cell subsets and innate-like T cells in shaping the phenotype of the pathological process and their complex role in regulating the immunopathogenesis of T1D and T2D. Conclusion: In this pilot study, we provide evidence that different subpopulations of NK cells and innate-like T cells are involved in the immunopathogenesis of T1D and T2D: an acute elevation of CD8+ NK cells was associated with T1D, while loss of circulating MAIT cells was a hallmark of T2D.

Keywords: Type 1 and Type 2 diabetes mellitus, autoimmune inflammation, NK cells, NK8+, CD38, CD161, NKG2A, innate-like T cells

Received: 17 Jul 2025; Accepted: 07 Nov 2025.

Copyright: © 2025 Loguinova, Sergeev, Samsonova, Sorokina, Grebennikov, Golodnikov, Goncharenko, Bocharov, Laptev, Khusainova, Minniakhmetov, Shestakova, Dedov and Mokrysheva. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Marina Loguinova, loginova.marina@endocrincentr.ru

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.